Suggestions
Panos Kanavos
Deputy Director at LSE Health, London School of Economics
Panos Kanavos is a prominent academic and expert in international health policy at the London School of Economics (LSE). He holds several key positions within the institution:
Academic Roles
- Associate Professor in International Health Policy in the Department of Health Policy at LSE23
- Reader in International Health Policy1
- Senior Lecturer in International Health Policy1
Leadership Positions
- Deputy Director at LSE Health14
- Programme Director for the MSc in International Health Policy1
- Director of the International Health Policy Programme (Health Economics) at LSE Health5
Research Focus
Dr. Kanavos specializes in international health policy, with a particular emphasis on health economics and medical technology research.5 His expertise makes him a valuable contributor to discussions on global health issues and policy-making.
Professional Engagement
Beyond his academic roles, Panos Kanavos is actively involved in sharing his knowledge and insights:
- He participates in expert discussions and roundtables on life sciences and health policy4
- His work is recognized by international organizations, as evidenced by his profile on the Commonwealth Fund website5
Panos Kanavos can be found on professional networking platforms, with the LinkedIn username "panos-kanavos-95760512" as mentioned in the query.1
Highlights
In our latest #research article on #healthtechnologyassessment with Erica Visintin and Arianna Gentilini, we analyse a dataset of 1415 drug-indication pairs to empirically determine the factors associated with positive HTA outcomes across 7 OECD countries, the time to achieve these and establish the magnitude of inter-country differences in assessment processes. We found that positive HTA outcomes accounted for 87.3% of the sample, of which 71% were restricted. #newdrugs with positive HTA outcomes were subject to clinical restrictions (46%), financial risk-sharing (31%) or had been rejected at least once (20%). Significant predictors of positive HTA outcomes were orphan drugs with cancer indications, high quality of evidence linked to clinical and economic evidence uncertainties which had been overcome, and contextual considerations, particularly innovativeness and unmet need. Comparative analyses revealed systematic differences between countries in their propensity to accept the same drugs, particularly oncology and orphan drugs. The article can be accessed here: https://lnkd.in/e7UcUXqT
